Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)

This study has been completed.
Information provided by (Responsible Party):
Prof. Dr. Andreas Engert, University of Cologne Identifier:
First received: August 19, 2010
Last updated: October 30, 2015
Last verified: October 2015
The purpose of this trial is to determine the efficacy of ofatumumab in patients with relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).

Condition Intervention Phase
Relapsed NLPHL
Drug: Ofatumumab
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Ofatumumab in Relapsed Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)

Resource links provided by NLM:

Further study details as provided by Prof. Dr. Andreas Engert, University of Cologne:

Primary Outcome Measures:
  • Overall response rate [ Time Frame: 12 months after end of treatment ]

Secondary Outcome Measures:
  • duration of response [ Time Frame: 12 months after end of treatment ]
  • Progression free survival [ Time Frame: 12 months after end of treatment ]
  • adverse events [ Time Frame: 12 months after end of treatment ]

Enrollment: 28
Study Start Date: May 2011
Study Completion Date: September 2015
Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Ofatumumab
    300 mg/m2 d1 week 1 1000mg/m2 d1 week 2-8

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • relapsed nodular lymphocyte predominant hodgkin lymphoma
  • age 18 - 75
  • review of diagnosis by experienced pathologist
  • no major organ dysfunction

Exclusion Criteria:

  • classical hodgkin lymphoma
  • CD20 antibody treatment within the last 6 months prior enrollment
  • chronic or current infectious disease requirering systemic antibiotics
  • other past or current malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01187303

1st Department of Medicine, Cologne University Hospital
Cologne, Germany
Sponsors and Collaborators
University of Cologne
Principal Investigator: Andreas Engert, MD University of Cologne
  More Information

Additional Information:
Responsible Party: Prof. Dr. Andreas Engert, Prof., University of Cologne Identifier: NCT01187303     History of Changes
Other Study ID Numbers: Uni-Koeln-1432
Study First Received: August 19, 2010
Last Updated: October 30, 2015

Additional relevant MeSH terms:
Hodgkin Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on May 25, 2017